Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Investment analysts at HC Wainwright increased their FY2029 earnings estimates for shares of Aldeyra Therapeutics in a note issued to investors on Monday, May 19th. HC Wainwright analyst M. Caufield now forecasts that the biotechnology company will post earnings per share of $1.10 for the year, up from their previous estimate of $1.00. HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Aldeyra Therapeutics' current full-year earnings is ($0.92) per share.
Separately, BTIG Research dropped their target price on shares of Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a report on Monday, April 7th.
View Our Latest Stock Analysis on ALDX
Aldeyra Therapeutics Stock Performance
NASDAQ:ALDX opened at $2.42 on Tuesday. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18. The firm has a 50-day moving average price of $3.47 and a two-hundred day moving average price of $4.71. Aldeyra Therapeutics has a twelve month low of $1.14 and a twelve month high of $7.20. The company has a market capitalization of $144.95 million, a P/E ratio of -2.49 and a beta of 0.92.
Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.08.
Insider Buying and Selling
In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of Aldeyra Therapeutics stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the transaction, the insider now directly owns 5,875,851 shares of the company's stock, valued at $8,343,708.42. The trade was a 36.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 9.60% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its holdings in Aldeyra Therapeutics by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 1,119,555 shares of the biotechnology company's stock valued at $5,588,000 after acquiring an additional 4,927 shares in the last quarter. Kingdon Capital Management L.L.C. bought a new stake in Aldeyra Therapeutics during the first quarter valued at $4,479,000. Dimensional Fund Advisors LP increased its stake in Aldeyra Therapeutics by 21.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 735,763 shares of the biotechnology company's stock valued at $3,672,000 after purchasing an additional 131,722 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Aldeyra Therapeutics during the fourth quarter valued at $3,628,000. Finally, ADAR1 Capital Management LLC increased its stake in Aldeyra Therapeutics by 114.4% during the fourth quarter. ADAR1 Capital Management LLC now owns 647,960 shares of the biotechnology company's stock valued at $3,233,000 after purchasing an additional 345,748 shares during the last quarter. 59.71% of the stock is owned by institutional investors and hedge funds.
Aldeyra Therapeutics Company Profile
(
Get Free Report)
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aldeyra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aldeyra Therapeutics wasn't on the list.
While Aldeyra Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
